MedTrace Logo

Design of Chatbot Persona for Breast Cancer Screening Outreach Among Black Women

NCT05472064 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2023-05-16

No results posted yet for this study

Summary

Breast cancer screening disparities among Black women persist despite health system recognition and outreach. However, current evidence on how to tailor and optimize implementation strategies for breast cancer screening outreach is limited. The proposed study is part of a larger project to design a chatbot for breast cancer screening outreach to Black women and will focus on optimizing the chatbot persona. Using the Multiphase Optimization Strategy (MOST) framework, the investigators will conduct a randomized factorial experiment to assess the individual components of chatbot persona for breast cancer screening and identify which components have the greatest effect on trust and engagement for Black women. This information will guide the design of an optimized chatbot intervention that achieves the primary outcomes.

Conditions

Interventions

OTHER

Persona: Primary care doctor

The chatbot persona is a Black woman who is a primary care doctor.

OTHER

Persona: Breast cancer survivor

The chatbot persona is a Black woman who is a breast cancer survivor.

OTHER

Communication Style: Direct

The chatbot messages are characterized by commands and direct addresses (''you'').

OTHER

Communication Style: Indirect

The chatbot messages are characterized by subjunctive modal verb forms (''would like'') and cooperative addresses (''we", "let's").

Sponsors & Collaborators

Principal Investigators

  • Leah Marcotte, MD · University of Washington

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-22
Primary Completion
2022-12-27
Completion
2022-12-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05472064 on ClinicalTrials.gov